Fidelity Investments
AKRO

Fidelity Investments’s Akero Therapeutics AKRO Stock Holding History

Fidelity Investments’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,079,657
Closed -$51.3M – 5417
2025
Q3 		$51.3M Buy
1,079,657
+147,731
+16% +$7.15M ﹤0.01% 1430
2025
Q2 		$49.7M Sell
931,926
-77,201
-8% -$3.51M ﹤0.01% 1401
2025
Q1 		$40.8M Buy
1,009,127
+970,403
+2,506% +$41.1M ﹤0.01% 1423
2024
Q4 		$1.08M Buy
38,724
+8,387
+28% +$254K ﹤0.01% 2644
2024
Q3 		$870K Buy
30,337
+26,691
+732% +$696K ﹤0.01% 2641
2024
Q2 		$85.5K Sell
3,646
-6,834
-65% -$146K ﹤0.01% 3364
2024
Q1 		$265K Buy
10,480
+7,408
+241% +$178K ﹤0.01% 2935
2023
Q4 		$71.7K Sell
3,072
-2,747,276
-100% -$54.2M ﹤0.01% 3356
2023
Q3 		$139M Buy
2,750,348
+162,820
+6% +$7.58M 0.01% 841
2023
Q2 		$121M Buy
2,587,528
+1,446,243
+127% +$66.3M 0.01% 908
2023
Q1 		$43.7M Buy
1,141,285
+1,120,874
+5,492% +$50M ﹤0.01% 1310
2022
Q4 		$1.12M Sell
20,411
-18,460
-47% -$791K ﹤0.01% 2510
2022
Q3 		$1.32M Buy
38,871
+38,289
+6,579% +$586K ﹤0.01% 2539
2022
Q2 		$5K Buy
+582
New +$6.07K ﹤0.01% 4294

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fidelity Investments's AKRO Position: Q4 2025 in Review

Fidelity Investments sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,079,657 shares — an estimated $51.3M sold.

Fidelity Investments first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $139M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Fidelity Investments reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fidelity Investments sold 1,079,657 Akero Therapeutics shares in Q4 2025, an estimated $51.3M.
  • Fidelity Investments first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • Fidelity Investments's Akero Therapeutics position peaked at $139M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.